EXPERIMENT 15-16 POST LAB: SUMMARY OF THE E HEPATITIS VIRUSES AND THEIR ASSOCIATED SEROLOGICAL AND MOLECULAR MARKERS Flashcards
RNA Picornaviridae
HAV
Fecal, oral
HAV
HEV
Progression to Chronic State: No
HAV
HEV
Progression to Chronic State: Yes
HBV
HCV
HDV
DNA Hepadnaviridae
HBV
Parental, sexual, perinatal
HBV
HCV
RNA Flaviviridae
HCV
RNA Genus Deltavirus
HDV
RNA Hepeviridae
HEV
Low risk of fulminant liver disease
HAV
10 to 90 percent of cases may develop chronic hepatitis (depending on age), with increased risk for liver cirrhosis and hepatocellular carcinoma
HBV
Eighty-five percent develop chronic infection, with increased risk of cirrhosis, hepatocellular carcinoma, or autoimmune manifestation
HCV
Increased risk of developing fulminant hepatitis, cirrhosis, or hepatocellular carcinoma
HDV
Fulminant liver failure in pregnant women
HEV
Acute hepatitis A
IgM anti-HAV
Immunity to hepatitis A
Total anti-HAV
Detection of HAV in clinical, food, or water samples
HAV RNA
Active hepatitis B infection
Active hepatitis B with high degree of infectivity
HBsAg
Current or recent acute hepatitis B
IgM anti-HBc
Current or recent acute hepatitis B
Total anti-HBc
Recovery from hepatitis B
anti-HBe
Immunity to hepatitis B
anti-HBs
Current or past hepatitis C infection
Anti-HCV
Current hepatitis C infection
HCV RNA
viral may be used to monitor effectiveness of therapy
HCV RNA
also used to determine HCV genotype
HCV RNA
Acute or chronic hepatitis D
IgM-anti-HDV
Recovery from hepatitis D or chronic hepatitis D
IgG-anti-HDV
Active HDV infection; viral load may be used to monitor effectiveness of therapy
HDV RNA
Current hepatitis E infection
IgM anti-HEV
Current of part hepatitis E infection
IgG anti-HEV
Current hepatitis E infection
HEV RNA
Acute, atypical, or occult hepatitis B; viral load may be used to monitor effectiveness of therapy
anti-HBs
